Researchers have identified a previously unknown mechanism by which the kidney precisely controls calcium excretion. The claudin-14 protein plays a key role in this process: It displaces the ...

New data from the landmark FLOW trial, which linked the glucagon peptide 1 (GLP-1) receptor agonist semaglutide with significant kidney outcomes in patients with type 2 diabetes (T2D) and chronic ...

Please provide your email address to receive an email when new articles are posted on . Semaglutide benefits were observed for adults with type 2 diabetes and chronic kidney disease whether or not ...

Scientists have discovered new chronic kidney disease treatment options in 2025-2026, from finerenone for non-diabetic CKD to ...

Please provide your email address to receive an email when new articles are posted on . Semaglutide lowered risk for kidney outcomes consistently across BMI subgroups in the FLOW trial. Body weight ...

Kidneys rarely demand attention—until something goes wrong. Every day, these bean-shaped organs filter waste, balance fluids, ...

Bagsværd, Denmark, 10 October 2023 – Novo Nordisk today announced the decision to stop the kidney outcomes trial FLOW (Effect of semaglutide versus placebo on the progression of renal impairment in ...

STOCKHOLM — Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, has shown significant benefits in preventing major kidney disease, cardiovascular events, as well as mortality in patients ...

For a study weighing the injectable semaglutide in chronic kidney disease, an early end appears to give Novo Nordisk cause to celebrate. Novo on Tuesday said it decided to stop its kidney outcomes ...

Winston-Salem, N.C. – A pilot study suggests that the results of minimally invasive angioplasty and stenting to restore blood flow to the kidneys can be significantly improved if a suction device is ...